ThermoGenesis Holdings Inc. (THMO) - Long-Term Indebtedness

Symbol and logo of brand Cesca Therapeutics (THMO)

The market price action of ThermoGenesis (THMO) reflects the dynamics of long-term liabilities, which currently stand at 0.00. The business relies on US-based plants that develop systems for regenerative therapy. Automated installations for biobanks generate revenue, creating demand for proprietary consumables. Consistent sales of stem cell processing cartridges ensure a steady cash flow and confirm the relevance of current technological solutions.

THMO (ThermoGenesis Holdings Inc.) Company Long-Term Debt history from 07/04/2022 to 08/04/2024

Metric breakdowns and analytics for ThermoGenesis Holdings Inc. (THMO)

- price and consensus price forecast:
Stock Price thermogenesis.com|THMO - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization ThermoGenesis|THMO - Total Company Value
- book capitalization data:
Equity per Share ThermoGenesis|THMO - Company Book Value|Market-to-Book Ratio thermogenesis.com|THMO - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Capital Coefficient ThermoGenesis|THMO - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Cesca Therapeutics|THMO - Company Aggregate Debts|Debts to Net Assets ThermoGenesis|THMO - Company Long-Term Debts|Company Current Liabilities ThermoGenesis
General company analysis:THMO (thermogenesis.com)
Mass-produced product of ThermoGenesis Holdings, Inc.

Assessing the reliability of equity assets begins with an analysis of the debt load. This indicator captures the total volume of credit obligations with a maturity of more than one year. For ThermoGenesis (THMO), such funds may be directed toward production modernization in line with ESG waste recycling standards. Rising borrowing increases financial risks as credit costs climb. The trend in the issuer's long-term liabilities allows for the determination of the balance between growth and stability.

Competitor analysis for ThermoGenesis

Company Long-Term Debts abbott.com ABT|Company Long-Term Debts TMO|GEHC: Long-Term Indebtedness|Company Long-Term Debt Mettler-Toledo International Inc.|WAT (Waters Technologies) - Company Long-Term Indebtedness|Company Long-Term Debt TECH (Bio-Techne Corporation)|Long-Term Debt BRKR|AZTA (Azenta) - Company Long-Term Debt|Long-Term Debt Volume Varex Imaging Corp VREX|Company Long-Term Liabilities Semler Scientific Corp (SMLR)|Amount of Long-Term Liabilities Butterfly Corp BFLY|Company Long-Term Debts MLAB (Mesa Laboratories, Inc.)|QSI - Long-Term Debt Volume|NNOX (Nano-X) - Company Long-Term Debts|Company Long-Term Liabilities Quanterix Corp.|MASS - Company Long-Term Liabilities|Company Long-Term Loans and Borrowings CV|Company Long-Term Debt MXCT (MaxCyte, Inc.)|Company Long-Term Liabilities rapidmicrobio.com (RPID)|SEER: Company Long-Term Debts|Long-Term Debt Hyperfine Inc HYPR|FONAR Corp (FONR) - Company Long-Term Debts|DXR - Company Long-Term Indebtedness|Spectral AI, Inc. - Company Long-Term Debts|Organovo (VIVS) - Long-Term Debt Volume|Company Long-Term Debts ACON|Company Long-Term Liabilities Akoya|Company Long-Term Debts TLIS|Company Long-Term Debts TTOO (T2 Biosystems Inc)